Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)

Stereotactic Body Radiotherapy (SBRT) is a standard treatment for inoperable primary and secondary lung tumors. In case of ultracentral tumor location, defined as tumor contact with vulnerable mediastinal structures such as the proximal bronchial tree (PBT) or esophagus, SBRT is associated with an i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Regnery, Sebastian (VerfasserIn) , Ristau, Jonas (VerfasserIn) , Weykamp, Fabian (VerfasserIn) , Hoegen-Saßmannshausen, Philipp (VerfasserIn) , Sprengel, Simon David (VerfasserIn) , Paul, Katharina (VerfasserIn) , Buchele, Carolin (VerfasserIn) , Klüter, Sebastian (VerfasserIn) , Rippke, Carolin (VerfasserIn) , Renkamp, Claudia Katharina (VerfasserIn) , Pohl, Moritz (VerfasserIn) , Meis, Jan (VerfasserIn) , Welzel, Thomas (VerfasserIn) , Adeberg, Sebastian (VerfasserIn) , Körber, Stefan A. (VerfasserIn) , Debus, Jürgen (VerfasserIn) , Hörner-Rieber, Juliane (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2022
In: Radiation oncology
Year: 2022, Jahrgang: 17, Pages: 1-6
ISSN:1748-717X
DOI:10.1186/s13014-022-02070-x
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13014-022-02070-x
Volltext
Verfasserangaben:Sebastian Regnery, Jonas Ristau, Fabian Weykamp, Philipp Hoegen, Simon David Sprengel, Katharina Maria Paul, Carolin Buchele, Sebastian Klüter, Carolin Rippke, Claudia Katharina Renkamp, Moritz Pohl, Jan Meis, Thomas Welzel, Sebastian Adeberg, Stefan Alexander Koerber, Jürgen Debus and Juliane Hörner-Rieber
Beschreibung
Zusammenfassung:Stereotactic Body Radiotherapy (SBRT) is a standard treatment for inoperable primary and secondary lung tumors. In case of ultracentral tumor location, defined as tumor contact with vulnerable mediastinal structures such as the proximal bronchial tree (PBT) or esophagus, SBRT is associated with an increased risk for severe complications. Magnetic resonance (MR)-guided SBRT can mitigate this risk based on gated dose delivery and daily plan adaptation. The MAGELLAN trial aims to find the maximum tolerated dose (MTD) of MR-guided SBRT of ultracentral lung tumors (ULT).
Beschreibung:Published 25 May 2022
Gesehen am 06.07.2022
Beschreibung:Online Resource
ISSN:1748-717X
DOI:10.1186/s13014-022-02070-x